All Updates

All Updates

icon
Filter
Funding
Generate Biomedicines raises USD 273 million in Series C funding
AI Drug Discovery
Sep 15, 2023
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
AI Drug Discovery

AI Drug Discovery

Sep 15, 2023

Generate Biomedicines raises USD 273 million in Series C funding

Funding

  • AI drug development company Generate Biomedicines has raised USD 273 million in a Series C funding round led by Amgen, with participation from NVentures, MAPS Capital, Pictet Alternative Advisors, and other existing investors. This brings the total fund raised by the company to USD 693 million.

  • The funds will support the advancement of the company’s pipeline of protein therapies, enhance its generative biology platform, pursue collaborations, and invest in new program starts. The company plans to file a Clinical Trial Application for its anti-TSLP monoclonal antibody by early Q4 2023 and initiate multiple clinical trials annually. In addition, Generate Biomedicines also aims to submit multiple Investigational New Drug (IND) applications in 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.